XNASCMPX
Market cap206mUSD
Dec 24, Last price
1.50USD
1D
-0.66%
1Q
-13.29%
IPO
-82.35%
Name
Compass Therapeutics Inc.
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
19.51%
Rev. gr., 5y
%
Revenues
0k
Net income
-42m
L+15.49%
CFO
-41m
L+19.03%
Profile
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
IPO date
Nov 13, 2020
Employees
26
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2020‑03 | 2019‑03 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 62,594 | 43,559 | 32,888 | |||
Unusual Expense (Income) | ||||||
NOPBT | (62,594) | (43,559) | (32,888) | |||
NOPBT Margin | ||||||
Operating Taxes | (2,430) | 370 | ||||
Tax Rate | ||||||
NOPAT | (62,594) | (41,129) | (33,258) | |||
Net income | (42,494) 15.49% | (36,795) -55.43% | (82,551) 137.60% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 3,094 | 76,237 | 128,267 | |||
BB yield | -1.56% | -14.41% | -64.36% | |||
| Debt | ||||||
Debt current | 1,197 | 1,097 | 989 | |||
Long-term debt | 1,072 | 4,773 | 7,085 | |||
Deferred revenue | ||||||
Other long-term liabilities | (1) | |||||
Net debt | (150,192) | (180,739) | (136,440) | |||
| Cash flow | ||||||
Cash from operating activities | (40,618) | (34,125) | (19,666) | |||
CAPEX | (30) | (212) | (1,568) | |||
Cash from investing activities | 26,965 | (151,200) | (1,770) | |||
Cash from financing activities | 2,935 | 75,757 | 118,611 | |||
FCF | (60,734) | (39,331) | (35,839) | |||
| Balance | ||||||
Cash | 152,461 | 186,609 | 144,514 | |||
Long term investments | ||||||
Excess cash | 152,461 | 186,609 | 144,514 | |||
Stockholders' equity | (315,258) | (273,103) | (233,579) | |||
Invested Capital | 469,619 | 457,676 | 377,694 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 127,027 | 105,186 | 62,870 | |||
Price | 1.56 -68.99% | 5.03 58.68% | 3.17 | |||
Market cap | 198,162 -62.55% | 529,086 165.47% | 199,298 | |||
EV | 47,970 | 348,347 | 62,858 | |||
EBITDA | (60,704) | (41,655) | (31,264) | |||
EV/EBITDA | ||||||
Interest | 2,360 | 370 | ||||
Interest/NOPBT | ||||||